内容概要：马鞍山作为长三角中心区27城之一，地处皖苏交汇地带，是南京都市圈与合肥都市圈的双重 节点城市。近年来，马鞍山锚定打造安徽的"杭嘉湖"、长三角的"白菜心"新发展定位，树牢领跑意识， 敢于创先争优，经济运行稳中有进，新质生产力发展壮大。马鞍山市深入践行新发展理念，系统构 建"四维驱动、梯次发展"的现代化产业体系。该体系以"传统产业转型升级、新兴产业集聚发展、未来 产业前瞻布局、现代服务业提质增效"为战略支点，形成层次分明、协同联动的产业新格局：传统产业 领域，推动钢铁、机械制造、化工等基础产业实施"智改数转"，加速向绿色化、精品化转型；新兴产业 领域，重点培育智能装备、轨道交通装备、高端数控机床等战略性产业，打造"1+3+N"战新产业集群矩 阵，发展新材料、生物医药、数字经济等特色产业；未来产业领域，聚焦人工智能等前沿方向，构 建"技术研发-场景应用-产业孵化"创新链条；现代服务业领域，着力提升物流枢纽、科技服务、文旅融 合等业态能级。通过产业链、创新链、资金链、人才链"四链融合"，推动全市产业体系向高端化、智能 化、绿色化方向高质量发展，形成传统产业筑基、新兴产业引领、未来产业蓄势、现代服务业赋能的良 ...

据介绍，相比以往赛事，本届大赛更加突出服务创新，通过组织赛前和赛后辅导、投融资对接等一 站式服务，提升大赛软实力。同时，郑州将全力营造"鼓励创新、支持创业、成就梦想"的一流生态，助 力参赛选手取得好成绩，赋能企业发展。 当前，郑州正全面落实"两高四着力"重大要求，锚定"科创强市"奋斗目标，勇挑重担，奋力在全省 科技创新中"挑大梁、走在前"。承办中国创新创业大赛，正是我市落实重大要求、激发创新活力、培育 新质生产力的生动实践和重要平台。 "中国创新创业大赛是全国创新创业领域的年度盛会，汇聚众多创业精英、学者和企业家。历届大 赛中，成功培育了中科清能、灵希生物、东微电子等一批明星企业，建成各级孵化载体300余家，逐步 构建起多层次、全链条的创新创业生态体系。"郑州市科技局相关负责人表示，"郑创汇"赛事已持续十 余年，已成为创新创业项目加速成长的"孵化器"，技术与市场精准对接的"金桥梁"，驱动经济社会高质 量发展的"强引擎"。 7月15日，第十四届中国创新创业大赛河南郑州分赛区暨2025"郑创汇"国际创新创业7月份大赛决赛 成功举办。决赛分为成长组与初创组，经过激烈角逐，成长组11个项目、初创组5个项目晋级省赛。 ...

问渠那得清如许，为有源头活水来——把发展特色优势产业作为主攻方向，久久为功，一张蓝图绘 到底。 一个地方的发展，关键在于找准路子、突出特色。以牡丹产业为例，牡丹是菏泽的一张亮丽名片， 经过多年的不懈努力，菏泽挖掘出"一朵牡丹花"的无限生机。作为全球最大的牡丹种植与科研加工基 地，近年来，菏泽市在品种培育、产业拓展、文旅融合等方面持续挖掘牡丹优势，目前已培育出9大色 系、10大花型、1308个品种，种植面积与品种数量均居世界首位。通过先进的反季节催花技术，打破花 期限制，每年春节期间，60余万盆菏泽牡丹销往全国各地，实现了"花开四季"的市场供应。 在产业发展层面，菏泽构建起从种植加工到旅游观光、文化创意的全产业链条。全市拥有牡丹生产 加工企业120余家，科研机构20所，开发出牡丹籽油、化妆品、保健品、文创产品等在内的260多种深加 工产品，去年牡丹产业总产值达130亿元。 从市到县，"特"字生辉。单县的羊肉汤产业同样可圈可点。单县把发展壮大羊肉汤产业作为县域经 济高质量发展的重要抓手，高位推动、一体谋划，紧盯打造百亿级特色产业目标，在"短链"延长、"断 链"连通、"细链"增粗、"弱链"变强上聚力攻坚，以新质生产 ...

作者｜企业家记事 编辑｜MAX 来源｜蓝筹企业评论 一位从山西走出的女企业家创造了最新的财富故事。 始人杨霞 锦波生物创 被称为"北交所明星"的锦波生物，它的创办人杨霞以"再造人体青春蛋白"为使命，将锦波生物从50万启 动资金的小微企业，发展为市值超200亿的生物材料龙头。 杨霞的"人源化胶原蛋白"帮助她的公司获取医美产业的高额利润，并带来更为宏大的愿景——"让重组 胶原蛋白成为继钢铁、碳纤维后的第三代基础材料"。 杨霞2008创立公司面临着三重困境： 无实验室，团队在山西医科大学租赁场地开展实验，设备简陋；无技术参照，全球尚无重组人源化胶原 蛋白成功案例；资金链紧绷，初始50万元资本耗尽后，依靠政府补贴维系研发。 技术突破于2014年。杨霞团队成功研制出第一款重组Ⅲ型胶原蛋白产品，首次实现重组Ⅲ型胶原蛋白上 市。 持续7年攻关后，2018年迎来里程碑突破：利用X射线衍射技术，解析出Ⅲ型胶原蛋白核心功能区—— 由30个氨基酸（残基704–733）构成的高活性区域；在国际上首次完成重组人源化胶原蛋白原子结构复 刻，获中国发明专利。 产业化落地2019年，锦波生物建成全球首条重组人源化胶原蛋白生产线。2021年6 ...

活动现场打破传统的"排排坐模式"，布置多张小型洽谈圆桌，杭州启飞智能科技有限公司、浙江兆奕科 技有限公司、杭州矢崎配件有限公司等钱塘企业作为采购商与参展商同桌交流。"我们想在生产过程中 引进海外较为先进的工厂数字管理技术，来参加路演活动就是想寻找合适的供应商。"这是来自采购商 的声音；"路演是一个提前挖掘客户、提前接新单的机会。"这是来自参展商的声音。通过路演，双方打 破距离边界，建立直接联系，为"提前接单、提前采购"奠定了基础。中国国际进口博览局有关负责人在 与钱塘企业接洽后表示，钱塘区内"车药芯化航"五大主导产业初具规模，国家高新技术企业、专精特新 企业和上市企业林立，还拥有智能汽车及智能装备、生物医药、新材料、集成电路等千亿级和500亿级 产业集群，产业基础雄厚，营商环境优越，希望以进博会为平台，通过路演活动主动对接高端参展商和 客商资源，为实现进博会"越办越好"打造样板。 会上，中国国际进口博览局与浙江省国际贸易集团供应链有限公司、浙江省粮油食品进出口股份有限公 司、银泰商业集团、杭州启耀新材料有限公司、龙焱能源科技（杭州）股份有限公司分别签署了重要采 购商合作备忘录。 据悉，第八届进博会企业商业展已 ...

智通财经APP讯，领航医药生物科技(00399)发布公告，于2025年7月15日，本公司与认购人A张彪兵订 立认购协议A，认购人A有条件同意认购而本公司有条件同意配发及发行合共6000万股股份，认购价A 为每股认购股份A 0.312港元。认购股份A将根据一般授权配发及发行。 认购价A和认购价B较股份于2025年7月15日(即认购协议A日期)在联交所所报的收市价每股0.39港元折 让约20%。 该等认购事项所得款项总额及所得款项净额将分别为约2808万港元及2778万港元，拟用作本集团的一般 营运资金。 董事认为，考虑到近期市况对本集团而言是巩固其资本基础及财务状况的良机，透过发行认购股份筹集 资金属合理。董事认为，发行认购股份是筹集额外资金的适当途径，因为该等认购价较上文所载市价有 所折让，而此乃经本公司分别与该等认购人公平磋商后达致。 假设本公司已发行股本于本公告日期至完成期间并无变动，认购股份A占于本公告日期本公司现有全部 已发行股本约3.00%;及本公司经发行认购股份扩大后全部已发行股本约2.92%。 于2025年7月15日，本公司与认购人B陈静订立认购协议B，认购人B有条件同意认购而本公司有条件同 意 ...

中国神华净利润额位居榜首 南方精工成为半年报"预增王" 从预告净利润变动幅度上限来看，869家上市公司预计上半年净利润同比增长，占比56.98%。其中， 428家公司预计上半年净利润同比增长100%以上，118家公司预计上半年净利润同比增长300%以上，62 家公司预计上半年净利润同比增长500%以上，40家公司预计上半年净利润同比增长800%以上，33家公 司预计上半年净利润同比增长1000%以上，14家公司预计上半年净利润同比增长2000%以上，4家公司 预计上半年净利润同比增长3000%以上。南方精工以35784%增幅成为半年报"预增王"，华银电力以 4423%增幅位居第二，三和管桩以3889%增幅位居第三。 7月15日，A股中报业绩预告披露收官。据同花顺数据统计，截至7月15日，A股共有1525家上市公司披 露了2025年中报业绩预告，其中预喜公司662家（预增414家、续盈6家、扭亏189家、略增53家），占比 43.41%；预忧公司857家（预减198家、续亏429家、首亏214家、略减16家），占比56.19%；不确定公 司6家，占比0.40%。从行业分布来看，生物医药、基础化工、人工智能、半导 ...

Core Points - The report indicates that Wang Haibo has reduced his shareholding in Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. from 5.41% to 5.00%, marking the first time his holding has fallen below 5% [1][4] - The reduction was executed through centralized bidding, with a total of 4,270,722 shares sold, representing 0.41% of the company's total share capital [4][8] - The purpose of this share reduction is attributed to Wang Haibo's personal funding needs, as stated in the previously announced reduction plan [3][4] Summary by Sections Section 1: Definition - The report defines key terms, including the information disclosure obligor (Wang Haibo) and the company (Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd.) [2] Section 2: Information Disclosure Obligor - Wang Haibo is identified as the information disclosure obligor, with no other significant shareholdings in other listed companies [3] Section 3: Purpose of Equity Change - The equity change is primarily driven by Wang Haibo's funding needs, as outlined in a prior announcement regarding the reduction plan [3][4] Section 4: Method of Equity Change - Prior to the equity change, Wang Haibo held 56,099,327 shares (5.41% of total shares). After the reduction, he holds 51,828,605 shares (5.00%) [4][6] - The shares were sold between July 14 and July 15, 2025, through centralized bidding [4][8] Section 5: Trading History - There were no other transactions involving the company's shares by Wang Haibo in the six months preceding the report [5][8] Section 6: Other Significant Matters - The report confirms that all relevant information regarding the equity change has been disclosed accurately and completely [6][8]

Core Viewpoint - The announcement details a change in shareholding by major shareholder Wang Haibo, who has reduced his stake in Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. to 5% through a planned share reduction, which does not trigger a mandatory takeover bid [1][2]. Summary by Sections 1. Basic Information of the Shareholder - Wang Haibo is a Chinese national and holds permanent residency in Hungary [1]. 2. Details of the Shareholding Change - Wang Haibo reduced his shareholding from 56,099,327 shares (5.41%) to 51,828,605 shares (5.00%) by selling 4,270,722 shares through centralized bidding from July 14 to July 15, 2025 [1]. - The reduction in shareholding does not affect the control of the company as there is no controlling shareholder or actual controller [1][2]. 3. Shareholding Status Before and After the Change - Before the change: Wang Haibo held 56,099,327 shares (5.41% of total share capital) - After the change: Wang Haibo holds 51,828,605 shares (5.00% of total share capital) [1]. 4. Compliance with Regulations - The shareholding change complies with relevant regulations and does not violate any laws or guidelines regarding shareholder reductions [3].

Core Viewpoint - Hainan Free Trade Port offers a comprehensive tax incentive system, including zero tariffs, low tax rates, and simplified tax regulations, effective from 2025, aimed at attracting businesses and fostering economic growth [1]. Group 1: Corporate Income Tax - Hainan's corporate income tax policy features "universal applicability + special care," with core policies extended until the end of 2027, providing long-term tax stability for businesses [3]. - A unified corporate income tax rate of 15% will apply to all registered companies in Hainan, significantly lower than the mainland's 25% standard rate, with additional exemptions for certain industries [4]. - Companies in encouraged industries can enjoy further tax benefits if their main business revenue exceeds 60% of total income, including exemptions on overseas direct investment income [4]. Group 2: Import Taxation - The zero-tariff list has expanded to 453 items, allowing companies to import raw materials without tariffs, VAT, or consumption tax, significantly reducing production costs [7]. - Companies producing goods with over 30% added value from imported materials can also benefit from tariff exemptions when selling to the mainland [9]. - The zero-tariff policy for transportation and tourism-related imports has been optimized, continuing to support the industry [10]. Group 3: Personal Income Tax - Hainan's personal income tax system offers dual-track incentives for high-end talent and ordinary residents, making it one of the most competitive in the country [12]. - High-end talent earning over 300,000 yuan annually can have their effective tax burden capped at 15%, significantly reducing their tax liabilities compared to the mainland [13]. - Ordinary residents will be taxed at a lower progressive rate of 3%, 10%, and 15%, compared to the mainland's higher rates [14]. Group 4: Specific Industry Incentives - Hainan has introduced a combination of "zero tariffs + special subsidies + facilitation measures" for key industries such as tourism, high-tech, and biomedicine [15]. - The medical tourism pilot zone allows for zero tariffs on imported drugs and medical devices, significantly reducing costs for patients [16]. Group 5: VAT Transition and Sales Tax Reform - 2025 marks a critical year for tax reform in Hainan, with transitional VAT policies and plans for a simplified sales tax system post-closure [17]. - The sales tax will combine various taxes, potentially lowering rates, requiring businesses to adapt their operational models accordingly [20]. Group 6: Policy Applicability and Compliance - To benefit from Hainan's tax incentives, companies must meet "substantive operation" requirements, avoiding the status of "shell companies" [22]. - Companies must apply for zero-tariff qualifications through the "Hainan International Trade Single Window," with tax benefits subject to verification by tax authorities [23]. Group 7: Case Studies - A cross-border e-commerce company utilized the zero-tariff policy on imported raw materials, achieving a significant reduction in overall tax burden [24]. - A biopharmaceutical company registered in Hainan benefited from reduced corporate income tax and R&D expense deductions, leading to substantial tax savings [24].